Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 2670

EyePoint shares more mid-stage data for therapy trying to compete with Regeneron's Eylea

$
0
0
EyePoint Pharmaceuticals, a biotech attempting to grab a sliver of Regeneron's share of the degenerative eye disease market, said six-month results show its drug met the primary endpoint in a Phase 2 trial. At first ...

Viewing all articles
Browse latest Browse all 2670

Trending Articles